|
Match
|
Document |
Document Title |
|
|
7351855 |
Chemically defined non-polymeric valency platform molecules and conjugates thereof
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
|
|
|
7208156 |
Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
|
|
|
7163683 |
Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
|
|
|
7138244 |
Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
|
|
|
7115581 |
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
|
|
|
7083959 |
Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
The present invention relates to a method of specifically suppressing an undesired immune response in a mammal suffering from such a response. The method comprises:
i) preparing a construct...
|
|
|
7081242 |
Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
The invention provides methods identifying individuals suitable for treatment for lupus and methods of monitoring treatment, based on measuring antibody affinities, as well as of treating lupus...
|
|
|
6951939 |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
Valency platform molecules comprising high molecular weight polyethylene oxide groups are provided, as well as conjugates thereof with biologically active molecules, and methods for their...
|
|
|
6897049 |
Proteins producing an altered immunogenic response and methods of making and using the same
The present invention relates to a novel methods and compositions for producing hyper and hypo allergenic compositions. Specifically, the present invention comprises neutralizing or reducing the...
|
|
|
6858210 |
Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
The present invention provides domain 1 β 2 GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 β 2 GPI polypeptides and...
|
|
|
6458953 |
Valency platform molecules comprising carbamate linkages
This invention pertains generally to valency molecules, such as valency platform molecules which act as scaffolds to which one or more molecules may be covalently tethered to form a conjugate. More...
|
|
|
6410775 |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL...
|
|
|
6399578 |
Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
This invention provides conjugates useful for xenotransplantation which comprise a galactose α1,3 galactosyl (αGal) epitope conjugated to a valency platform molecule, preferably a chemically...
|
|
|
6245752 |
Compositions and methods for tolerization in immune complex-mediated disease progression
Methods and compositions are provided for tolerizing shed antigen-specific B cells involved in an immune complex-mediated disease progression. The composition comprises a substantially...
|
|
|
6207160 |
aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL...
|
|
|
6060056 |
Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
|
|
|
6048529 |
PVA or PEG conjugates of peptides for epitope-specific immunosuppression
The invention relates to a procedure for synthesis of well-defined conjugates of peptides to the tolerogenic polymer monomethoxypolyethylene glycol (mPEG) or polyvinyl alcohol (PVA). This method...
|
|
|
6031073 |
Cyclic polypeptides comprising a thioether linkage and methods for their preparation
This invention relates generally to cyclic polypeptides comprising a thioether linkage and methods for their preparation. More particularly, this invention relates to halogenated polypeptides...
|
|
|
5874409 |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
aPL analogs that (a) bind specifically to B cells to which the aPL epitope binds and (b) lack T cell epitope(s), methods preparing and identifying said analogs and methods of treatment using said...
|
|
|
5817752 |
Cyclic polypeptides comprising a thioether linkage and methods for their preparation
This invention relates generally to cyclic polypeptides comprising a thioether linkage and methods for their preparation. More particularly, this invention relates to halogenated polypeptides...
|